Next Generation Immunotherapies Market
Market Insights on Next Generation Immunotherapies covering sales outlook, demand forecast & up-to-date key trends
Next Generation Immunotherapies Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Next Generation Immunotherapies Market Snapshot (2023 to 2033)
The global next generation immunotherapies market is expected to reach a valuation of US$ 112.88 Billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 7.5% from 2023 to 2033. The majority of existing immunotherapies, along with checkpoint inhibitors, aim to improve the adaptive immune system's response, especially cytotoxic T cells, in order to combat cancer. As a result, this is anticipated to contribute to market expansion.
The market is being driven by the rising pervasiveness of oncology around the world, as well as an increase in research and development investments for the creation of breakthrough oncology therapeutic strategies. Furthermore, the existence of multiple organizations that permits immunotherapy studies is expected to drive market expansion. For instance, the Parker Institute for Cancer Immunotherapy partnered with scientists and commercial leaders to establish breakthrough immune therapeutic approaches for cancer. Based on the Global Cancer Observatory, the United States had approximately 2,281,658 cancer cases in 2020, with 612,390 cancer-related moralities.
On the other hand, North America is expected to lead the overall industry in terms of sales in 2021, owing to the existence of a huge number of prominent companies, in addition to numerous Strategic events organized by them. Furthermore, the rise in the incidence of disease, the existence of multiple government and non-government corporations that support cancer immunotherapy experiments, and the escalating authorization of novel drugs are bolstering the regional market growth. Asia Pacific is expected to expand at the highest rate during the forthcoming years. Several of the main factors leading growth are an upsurge in the aging population, a huge patient platform of an aimed disease, and improved medical facilities. The 7th Annual Immuno-Oncology Summit Europe, coordinated by CHI, reverts to London's Canary Wharf for three days of research and technology consultations on the latest breakthroughs in the creation of favorable immuno-oncology treatments. The Summit, scheduled for June 20-22, 2023, will feature four meeting programs ranging from techniques for Modulating the Tumor Microenvironment to numerous therapeutic approaches such as Next-Generation Cell-Based Immunotherapies, Bispecific/Multi-Specific Antibody Therapies, and Gamma Delta Immunotherapy.
Among the drug class segments, monoclonal antibodies had the highest market share in 2021. The elevated prescription percentage of monoclonal antibodies, as well as the focused impact of monoclonal antibodies, are credited to the segment's expansion. Owing to the increasing incidence of disease in conjunction with high treatment rates, growing awareness and enhanced diagnostic test of malignancies, and an elevated volume of hospitals that provides immunotherapies intervention, the hospital Pharmacies segment was the largest distribution channel segment in 2021. In addition, numerous patients, particularly seniors and those with serious respiratory infections, are placed on ventilation systems for intensive care. In certain cases, intravenous solutions are continuously administered to such patients in order to ensure proper nutrition. As a consequence, among the route of administration segments, the intravenous segment is anticipated to hold the highest proportion.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 112.88 Billion |
|
Anticipated Forecast Value (2033) |
US$ 268.84 Billion |
|
Projected Growth Rate (2023 to 2033) |
7.5% CAGR |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Next Generation Immunotherapies Demand Analysis vs. Forecast 2023 to 2033
Since mid-2019, a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has wreaked astounding havoc around the globe. This prompted global efforts to research therapeutic interventions and vaccines against SARS-COV-2, and certainly, multiple vaccines are now authorized for the case of emergencies usages. As a result, the industry for next-generation immunotherapies has grown significantly over the last few years.
Cancer immunotherapy and tumor microenvironment scientific studies have been at the frontlines of recent decades. Addressing immune checkpoints, especially programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1), has resulted in the emergence of the treatment of advanced cancers. As a result, during the projected timeline. As a result of the release of possible new therapies, the industry for next-generation immunotherapy is expected to grow positively in the years ahead. According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6.9%.
Which are Some Prominent Drivers of the Next Generation Immunotherapies Market?
Numerous government and non-government organizations are raising awareness to uplift market growth
The involvement of different administrations and non-government organizations that raise knowledge and encourage research is helping to expand the market. For example, the Cancer Research Institute funded over 118 clinical trials and invested approximately USD 475 million in analysis.
Furthermore, the Society for Immunotherapy of Cancer (SITC) is committed to enhancing treatment experience through the advancement of cancer care immunotherapy science and implementation. These organizations are collaborating with researchers and scholars to develop novel immunotherapy therapeutic strategies.
Rising funding for the development of novel therapeutics to stimulate Market Growth
Raising funding for the advancement of novel therapeutics is anticipated to increase R&D initiatives in order to establish the Industry for Next Generation Immunotherapies.
For instance, in June 2022, a community of Stanford scientists obtained US$ 13 million from Cancer Grand Challenges, a financing venture launched by Cancer Research UK and the National Cancer Institute in the United States. This investment will be used to establish next-generation immunotherapies, research extrachromosomal DNA, and investigate early-stage cancers.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
High Costs to Hinder Market Growth
However, the adverse effects of immunotherapy are expected to decrease the number of cancer treatments prescribed. The obtainable treatments are correlated with a variety of side effects, including pain, insomnia, exhaustion, nausea, and digestive disturbances.
These complications have an impact on patient's general quality of life, and handling them involves additional costs. Furthermore, long-term utilization of immunotherapeutic drugs may lead to severe organ harm and boost the number of incidents of organ failure.
Region-Wise Insights
What Makes North America the Largest Market for Next Generation Immunotherapies?
The disease's rising incidence steers the North American market
North America dominated the next generation immunotherapies marketplace in terms of revenue in 2021, owing to the rising large number of major players, as well as key Organizational activities to be adopted by them.
Besides that, the escalating incidence of the disease, the inclusion of numerous government and non-government groups that promote cancer immunotherapy experiments, and the rising approbation of novel pharmaceuticals are bolstering regional market development. For instance, the FDA in the United States authorized Opdivo (nivolumab) for the treatment of NSCLC in older patients in April 2022.
Furthermore, according to Thandra et al. (2021), 77,200 new cases of NHL were detected in the US in 2020, holding for 4.3% of all cancer diagnoses, with 19,900 mortalities in 2020, accounting for 3.3% of all cancer-related deaths.
Why is Asia Pacific Considered a Lucrative Region for the Next Generation Immunotherapies Market?
Significant number of cancer patients requiring treatment propels market growth
The market for next-generation immunotherapies in the Asia Pacific, specifically in China, India, and Japan, is anticipated to expand rapidly during the forthcoming years. This industry's growth is anticipated to be fueled by a huge pool of patients requiring treatment for cancer, soaring cancer incidence, assertive investment by industry participants, rising government expenditure on health coverage, and rising disposable income of the inhabitants, which will strengthen adherence to treatment. Furthermore, the dearth of stringent guidelines and liberalization in Asian countries contributes to Asia Pacific's favorability as a business.
Furthermore, growing regulatory authorizations of immune therapies in the region are spurring the region's growth. For instance, the National Medical Products Administration of China authorized Pembrolizumab and Durvalumab for the diagnosis of esophageal cancer and SCLC between 2020 and 2022.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
By Drug Class, Which Segment is Projected to Lead the Market?
Monoclonal Antibodies Segment is Estimated to Hold the Largest Share
Among the drug class, monoclonal antibodies dominated the market share of 71% in 2021, and are expected to grow at a stable pace over the forecast period. The elevated prescription percentage of monoclonal antibodies, the aimed impact of monoclonal antibodies, comparatively fewer adverse effects, and the positive business performance and revenues of foremost monoclonal antibodies such as Keytruda, Yervoy, and Opdivo all contribute to the segment's expansion. For instance, Bristol-Myers Squibb Company stated a 5% rise in Opdivo and Yervoy profits in Q1 2022 compared to Q1 2021.
By Distribution Channel, Which Segment is Projected to Lead the Market?
Hospital Pharmacies Segment is Estimated to Hold the Largest Share
With a market share of 56.71% in 2021, the hospital pharmacy segment dominated the industry. The rising adoption of immunotherapy in hospitals, along with increased hospitalization owing to an increase in oncology ailments, is fueling the expansion of hospital pharmacies.
Start-ups in the Next Generation Immunotherapies Market
To strengthen their market presence, players in the keratitis treatment market sector are introducing novel and unique product lines, and the above-mentioned start-ups have left no stone unturned. A few specific instances of significant keratitis treatment market start-ups are as follows:
- Crescendo Biologics was founded in 2007. Researchers at The Institute of Cancer Research, London, announced in December 2021 that they are collaborating with the Cambridge-based immuno-oncology organization Crescendo Biologics on the advancement of a potential 'next generation' immunotherapy. This latest research partnership will investigate the non-clinical therapeutics of Crescendo's drug candidate, CB307, in a wide range of experimental concepts to supplement its current clinical innovation.
- CytomX Therapeutics was established in 2008. CytomX and Regeneron declared a collaboration in November 2022 to establish interventional next-generation bispecific immunotherapies utilizing CytomX's Probody® and Regeneron's Veloci-Bi® technologies.
Market Competition
Key players in the next generation immunotherapies market are Bristol Myers Squibb, Regeneron Pharmaceuticals, MacroGenics, Boehringer Ingelheim, Mereo BioPharma, Huabo Biopharm, Sigma-Baldric, Avantor, Inc., Pall Corporation, AstraZeneca, ImmunAbs, IMBiologics, Novacell Technology Inc.
- Boehringer Ingelheim and 3T Biosciences declared a strategic partnership and licensing contract in January 2023 to research and advance next-generation cancer therapies to address high unfulfilled requirements.
- MacroGenics accomplished the Phase 2/3 research design for MGC018 in patients with metastatic castration-resistant prostate cancer(mCRPC) after a productive FDA conference in March 2022.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 112.88 billion |
|
Market Value in 2033 |
US$ 268.84 billion |
|
Growth Rate |
CAGR of 7.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Next Generation Immunotherapies Market Industry Survey
By Drug Class:
- Monoclonal Antibodies
- Antibody-drug Conjugates - ADC's
- Ace Inhibitors
- Immune Checkpoint Inhibitors
By Route of Administration:
- Intravenous
- Parenteral
- Intratumoral
- Subcutaneous
- Oral
By Distribution Channel:
- Hospital Pharmacies
- Clinical Pharmacies
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
What is the anticipated growth of the Next Generation Immunotherapies market until 2033?
FMI projects the global Next Generation Immunotherapies market to expand at a 7.5% value CAGR by 2033.
What is the estimated market value of the Next Generation Immunotherapies market expected in 2023?
The global Next Generation Immunotherapies market is estimated at a market value of US$ 112.88 Billion.
What is the estimated market value of the Next Generation Immunotherapies market expected in 2033?
The global Next Generation Immunotherapies market is expected to garner a market value of US$ 268.84 Billion.
Which region is forecast to be the most lucrative for Next Generation Immunotherapies market growth?
FMI has projected North America to be one of the key regions for the Next Generation Immunotherapies market.
Which are some prominent Next Generation Immunotherapies manufacturers?
Bristol Myers Squibb, Regeneron Pharmaceuticals, MacroGenics, Boehringer Ingelheim, Mereo BioPharma, Huabo Biopharm, Sigma-Baldric, Avantor, Inc., Pall Corporation, AstraZeneca, ImmunAbs, IMBiologics, Novacell Technology Inc.
Table of Content
1. Executive Summary | Next Generation Immunotherapies Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Monoclonal Antibodies 5.3.2. Antibody-drug Conjugates - ADC's 5.3.3. Ace Inhibitors 5.3.4. Immune Checkpoint Inhibitors 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Intravenous 6.3.2. Parenteral 6.3.3. Intratumoral 6.3.4. Subcutaneous 6.3.5. Oral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Clinical Pharmacies 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom (UK) 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Drug Class 14.1.2.2. By Route of Administration 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Drug Class 14.2.2.2. By Route of Administration 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Drug Class 14.3.2.2. By Route of Administration 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Drug Class 14.4.2.2. By Route of Administration 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Drug Class 14.5.2.2. By Route of Administration 14.5.2.3. By Distribution Channel 14.6. UK 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Drug Class 14.6.2.2. By Route of Administration 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Drug Class 14.7.2.2. By Route of Administration 14.7.2.3. By Distribution Channel 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Drug Class 14.8.2.2. By Route of Administration 14.8.2.3. By Distribution Channel 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Drug Class 14.9.2.2. By Route of Administration 14.9.2.3. By Distribution Channel 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Drug Class 14.10.2.2. By Route of Administration 14.10.2.3. By Distribution Channel 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Drug Class 14.11.2.2. By Route of Administration 14.11.2.3. By Distribution Channel 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Drug Class 14.12.2.2. By Route of Administration 14.12.2.3. By Distribution Channel 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Drug Class 14.13.2.2. By Route of Administration 14.13.2.3. By Distribution Channel 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Drug Class 14.14.2.2. By Route of Administration 14.14.2.3. By Distribution Channel 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Drug Class 14.15.2.2. By Route of Administration 14.15.2.3. By Distribution Channel 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Drug Class 14.16.2.2. By Route of Administration 14.16.2.3. By Distribution Channel 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Drug Class 14.17.2.2. By Route of Administration 14.17.2.3. By Distribution Channel 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Drug Class 14.18.2.2. By Route of Administration 14.18.2.3. By Distribution Channel 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Drug Class 14.19.2.2. By Route of Administration 14.19.2.3. By Distribution Channel 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Drug Class 14.20.2.2. By Route of Administration 14.20.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Bristol Myers Squibb 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Regeneron Pharmaceuticals 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. MacroGenics 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Boehringer Ingelheim 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Mereo BioPharma 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Huabo Biopharm 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Sigma-Aldrich 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Avantor, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Pall Corporation 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. AstraZeneca 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 16.1.11. ImmunAbs 16.1.11.1. Overview 16.1.11.2. Product Portfolio 16.1.11.3. Profitability by Market Segments 16.1.11.4. Sales Footprint 16.1.11.5. Strategy Overview 16.1.11.5.1. Marketing Strategy 16.1.12. IMBiologics 16.1.12.1. Overview 16.1.12.2. Product Portfolio 16.1.12.3. Profitability by Market Segments 16.1.12.4. Sales Footprint 16.1.12.5. Strategy Overview 16.1.12.5.1. Marketing Strategy 16.1.13. Novacell Technology Inc. 16.1.13.1. Overview 16.1.13.2. Product Portfolio 16.1.13.3. Profitability by Market Segments 16.1.13.4. Sales Footprint 16.1.13.5. Strategy Overview 16.1.13.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Asia Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 97: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033 Figure 99: Asia Pacific Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 101: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 103: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 109: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 110: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 111: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 112: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 113: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 114: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 117: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 118: MEA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: MEA Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
